Why the shares open lighter today

Holders of Britain's largest listed company will notice something on their screens this morning that looks, at a glance, like a fall. From today, 6 August 2026, AstraZeneca (LSE:AZN) shares trade ex-dividend for the group's first interim payment of the 2026 financial year. Anyone buying the stock from now on is not entitled to that distribution; anyone who held it at yesterday's close is. To keep the market fair between the two, the opening price is adjusted down mechanically by roughly the value of the dividend the buyer no longer receives. It is an accounting reality of the timetable, not a verdict on the business, and it reverses none of the company's underlying prospects.

The sum involved is modest against a share price in the low-to-mid four figures of pence. AstraZeneca declared a first interim dividend of $1.06 per share, equivalent to 79.5 pence or 10.32 Swedish kronor (AstraZeneca results, 26 July 2026). That is up from the $1.00 first interim paid a year earlier. Because the group reports and declares in US dollars, UK shareholders receive the sterling equivalent, fixed at a stated exchange rate, with payment due on 8 September 2026 (Hargreaves Lansdown dividend data, accessed 6 August 2026). Management has signalled an intention to lift the full-year 2026 dividend to $3.30 per share, from $3.22 in 2025, continuing a policy of a progressive dividend that the board aims to maintain or grow each year (AstraZeneca results, 26 July 2026).

A first half that kept the momentum

The ex-dividend date arrives barely a fortnight after half-year figures that gave the payment its context. Total revenue for the six months to 30 June rose 9% to $30.7bn, or 6% at constant exchange rates, with product sales of $28.9bn up 8% (5% at constant currency) and alliance revenue climbing 31% to $1.7bn as partnered medicines scaled (AstraZeneca H1 2026 results announcement, 26 July 2026). The distinction matters: total revenue folds in that alliance and a small slice of collaboration revenue on top of the drugs AstraZeneca sells directly, so the headline growth rate is not a like-for-like read on volumes alone.

Profitability outpaced the top line on the measure management prefers. Core earnings per share — the adjusted figure that strips out amortisation, impairments and certain one-off items — reached $5.21, up 12% (11% at constant currency). Reported EPS, which keeps those charges in, was $3.60 (AstraZeneca H1 2026 results, 26 July 2026). Investors weighing the shares should hold both numbers in view; the gap between them is where acquisition accounting and restructuring live.

Oncology still doing the heavy lifting

Cancer medicines remain the engine. Oncology revenue of $14.1bn accounted for 46% of the group total and grew 18% (15% at constant currency), comfortably ahead of the wider portfolio (AstraZeneca H1 2026 results, 26 July 2026). Within that, lung-cancer therapy Tagrisso brought in $3.8bn and immunotherapy Imfinzi $3.5bn, up 31%, while Calquence in blood cancers added $1.9bn. Enhertu, the breast-cancer treatment partnered with Daiichi Sankyo, generated combined sales of about $3.0bn, of which AstraZeneca recognised $1.7bn. Away from oncology, the cardiovascular and metabolic franchise led by Farxiga continues to be a core pillar of group sales, spanning heart failure, chronic kidney disease and diabetes, though it is not immune to the patent pressures discussed below. The breadth of that portfolio is part of what underpins the dividend, since it spreads reliance across several therapy areas rather than a single blockbuster.

The cost — and risk — of staying ahead

Sustaining that pipeline is expensive. Research and development spending rose 12% to $7.5bn in the half, roughly a quarter of revenue, with core R&D at $7.1bn (AstraZeneca H1 2026 results, 26 July 2026). That outlay funds a broad late-stage programme, but readers should treat pipeline candidates with care: an investigational medicine is not an approved one, and trials fail. The group's own $80bn total-revenue ambition for 2030, which it reaffirmed alongside these results, is explicitly framed as assuming "successes and setbacks" — a reminder that the target embeds clinical risk rather than removing it. Business development is part of the answer, with recent deals including worldwide rights to Zegfrovy (sunvozertinib) and a licence for a PDE3/4 inhibitor.

Patent expiry is the structural counterweight. AstraZeneca publishes a schedule of exclusivity dates for its key products precisely because loss of exclusivity, when generic or biosimilar competition arrives, can erode a medicine's sales quickly (AstraZeneca Patent Expiries of Key Marketed Products, February 2026). Tagrisso, Farxiga, Imfinzi and others face staggered expiries over the coming years, and the $80bn goal effectively assumes newer launches can outrun those declines.

America looms larger

Currency and geography are increasingly entwined for AstraZeneca. Reporting in dollars means sterling investors carry a translation effect in every figure — hence the routine split between actual and constant-currency growth. The United States already provides close to half of group revenue, and the company has leaned into that. In February 2026 it began trading directly on the New York Stock Exchange, replacing its former Nasdaq depositary receipts and giving what it described as equal weight to its UK, Swedish and US listings; London remains the primary listing (Yahoo Finance, 2 February 2026). Alongside that, AstraZeneca has pledged to invest $50bn in the US by 2030, including a large manufacturing site in Virginia (FiercePharma, 2025). The strategic logic is exposure to the world's biggest drug market and insulation from tariff and pricing politics; the risk is concentration.

A premium that has to be earned

None of this settles the central question hanging over the stock: valuation. AstraZeneca trades on a premium rating relative to the wider FTSE 100 and to several large-cap pharmaceutical peers, a premium justified by faster growth, oncology leadership and the 2030 ambition — but one that leaves little room for disappointment. A missed trial readout, an accelerated patent cliff or a currency swing can move a highly rated share sharply. Today's mechanical ex-dividend adjustment is none of those things; it is simply the market handing the dividend to yesterday's owners. Investors should judge the company on its cash generation, pipeline delivery and the durability of that premium, not on a one-day price change that says nothing about long-term returns. As ever, past performance is no guarantee of what follows, and nothing here is advice.